11.28
1.23%
-0.14
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Viatris Inc Aktie (VTRS) Neueste Nachrichten
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Viatris And Idorsia Forge Global Partnership For Breakthrough Heart Attack Treatments - MSN
VTRS: 3 Hidden Bargains in the Healthcare Sector - StockNews.com
Here's What to Expect From Viatris' Next Earnings Report - MSN
Viatris Inc. stock rises Monday, outperforms market - MarketWatch
Chris Davis Reduces Stake in Viatris Inc: A Strategic Portfolio Adjustment - GuruFocus.com
Viatris: Consolidate In 2025, Win In 2026How 'Phase 2' Of Business Plan May Play Out - Seeking Alpha
Here's What To Expect From Viatris' Next Earnings Report - Barchart
Lidocaine Patches Market Projected To Witness Substantial Growth, 2025-2032: Sanofi S.A., Viatris Inc., Galen - EIN News
Shell says head of downstream and renewables division Vigeveno to step down -January 23, 2025 at 02:27 am EST - Marketscreener.com
Taxanes Market: Projected Growth Trends through 2031 | Pfizer - openPR
Why Is Viatris Inc. (VTRS) Among the Best High-Yield Dividend Stocks to Invest In? - Insider Monkey
EU Antitrust Chief Ribera: Consumer Protections Remain Top Priority - PYMNTS.com
Is Viatris Inc. (VTRS) Among Wednesday’s Losers? - MSN
Viatris Launch Plans Continue To Drag On, But Confidence High On Quartet - News & Insights
Viatris Inc. stock falls Wednesday, underperforms market - MarketWatch
Viatris Inc (VTRS) Stock Price Down 4.56% on Jan 15 - GuruFocus.com
Is Viatris (VTRS) a Great Value Stock Right Now? - Yahoo Finance
Viatris firm in Cork paid $4bn of dividends as sales fell ahead of announced plant closure - Business Post
Systemic Lupus Erythematosus Pipeline Report 2024: Clinical Trials Progress and Therapeutic Advancements | Sanofi SA, Eli Lilly & Company, Viatris Inc., Novartis AG, GlaxoSmithKline, Roche - Barchart
Systemic Lupus Erythematosus Pipeline Report 2024: Clinical - openPR
Ophthalmic Drugs Global Market Report 2025: Innovations in Retinal Disorders, Glaucoma Drive Global Ophthalmic Medicines Surge - GlobeNewswire Inc.
Is Viatris (VTRS) the Best Medical Stock to Buy Under $20? - Insider Monkey
Viatris Enters Oversold Territory - Nasdaq
Viatris Stock: Is VTRS Outperforming the Healthcare Sector? - MSN
Mydriasis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Viatris/Ocuphire Pharma, Eyenovia, Rayner Surgical/Omeros, Eyenovia Inc - The Globe and Mail
Mydriasis Pipeline 2024: Clinical Trials Assessment, FDA - openPR
Another Disappointing Drug Import Alert from India - The People's Pharmacy
When (VTRS) Moves Investors should Listen - Stock Traders Daily
US FDA Blocks 11 Viatris Products, Except Four With Shortage Concerns - News & Insights
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Viatris to Present at the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace
Viatris to Present at the 43rd Annual J.P. Morgan Healthcare Con - GuruFocus.com
Viatris to Present at the 43rd Annual J.P. Morgan Healthcare Conference -January 07, 2025 at 07:00 am EST - Marketscreener.com
Maternal Mental Health Market Is Booming Worldwide 2025-2032 | - openPR
Viatris Inc. stock falls Monday, underperforms market - MarketWatch
Viatris (VTRS) Shares Cross 4% Yield Mark - Nasdaq
Viatris: Looking At High Free Cash Flow Yield As Business Stabilizes (NASDAQ:VTRS) - Seeking Alpha
FDA Blocks Viatris US Products With India Facility Import Alert - News & Insights
Fierce Pharma Asia—Roche, Innovent's ADC deal; Lessons from AZ's China probes; Viatris' warning letter - FiercePharma
Viatris Inc (VTRS)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus.com
Viatris Inc. stock falls Monday, still outperforms market - MarketWatch
Maternal Mental Health Market Set to Witness Significant Growth by 2024-2031: Canopie, Pfizer Inc, Viatris - EIN News
Viatris Inc. stock falls Friday, still outperforms market - MarketWatch
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):